{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"The proportion of patients who develop full donor CD3+ lymphocyte chimerism by day 30.\n\nFull chimerism is defined as \\>95% donor alleles by molecular profiling (Short Tandem Repeat analysis).","groups":[{"description":"Bone marrow stem cell transplant program to improve the outcome of allogeneic Bone Marrow Transplant for hematologic malignancies. Immunosuppression including cyclosporine will be given six days prior to transplant up to 21 days post transplant. CD34 selection and T cell depletion using Isolex 300i immuno-magnetic cell selection and immunosuppression during peri- transplant.","id":"OG000","title":"Bone Marrow Transplantation Using Nexell Isolex 300i"}],"paramType":"NUMBER","populationDescription":"Per protocol; only patients who survived to day 30 and were evaluable.","reportingStatus":"POSTED","timeFrame":"Day 30","title":"The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30","type":"PRIMARY","unitOfMeasure":"percentage of participants"}